Development of a customed designed oxygenation system combined with novel therapy to treat reperfusion injury following Neurovascular Thrombectomy.

开发定制设计的氧合系统与新疗法相结合，治疗神经血管血栓切除术后的再灌注损伤。

• 批准号: 10057485
• 金额: $ 44.58万
• 依托单位: CERFEFUZE MEDICAL UK LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10057485
• 关键词: Development; customed; designed; oxygenation; system

Reperfusion Injury paradoxical exacerbation of cellular dysfunction and death, post blood flow restoration to previously ischaemic tissues, post mechanical thrombectomy. Blood flow restoration is mandatory to save ischaemic tissues. However, reperfusion could compromise function/viability of range-of-organs such as heart, lung, kidney, gut, skeletal muscle and brain on their own or even cause l multi-system organ failure. Reperfusion injury is a multi-factorial process resulting in substantial life-threatening tissue destruction.Despite of its high occurrence and related mortality/morbidity/healthcare-burden, there is no treatment available to minimise RI post thrombectomy. Body's own repair mechanisms are all that is relied-upon to recover from the ischemic state. Use of therapeutics have failed as the damaging effect of the blood outweighs benefitsCerefuse Medical aims to bring about the next generation in medical device interventions for ischemic stroke. The mechanism of Reperfusion Injury isn't new to science but it is only now, with sufficient revascularisation rates achieved in stroke care that it is possible to bring this life changing therapy to patients.Previous attempts to use therapeutics have failed to reduce reperfusion injury in the brain. A contributing factor for this is likely the presence of toxic ions and free radicals in the tissue from the reintroduction of whole blood to the post ischemic tissue. In simple terms the damaging effect of the blood outweighs the benefits of the therapeutic agent.Cerefuse's disruptive approach aims to reduce tissue function without relying on pharmaceutical agents to have an effect on tissue (though they will be used to modify the salt profile of the blood).Through this project, Cerefuse will* Design/assemble functional prototype device that can successfully modify the blood parameters,* Design and implement an initial animal study to show safety and efficacy in minimising RI occurrence.* Develop _in-vitro_ models to evaluate blood parameters* Prepare regulatory-approvals-strategy* Solidify IP position

再灌注损伤对细胞功能障碍和死亡的悖论加剧，血液流经以前缺血组织，机械血栓切除术后。血流恢复是必须的，以节省缺血组织。然而，再灌注可能会损害心脏，肺，肾脏，肠道，骨骼肌肉和大脑等符合范围的功能/生存能力，甚至会导致L多系统器官衰竭。再灌注损伤是一个多因素过程，导致了大量威胁生命的组织破坏。尽管其发生率很高和相关的死亡率/发病率/医疗保健，但没有可用的治疗方法可以最大程度地减少RI后血栓切除术。身体自己的修复机制是从缺血状态中恢复的。使用治疗剂的使用失败了，因为血液的破坏作用超过了良好的医疗旨在为缺血性中风的医疗设备干预措施带来下一代。再灌注损伤的机制并不是科学的新事物，但直到现在，在中风护理中达到的足够的血运重建率，可以将这种生活改变治疗带给患者。使用治疗剂的尝试未能减少大脑中的再灌注损伤。为此，一个促成因素可能是组织中存在有毒离子和自由基，从全血的重新引入到缺血性组织。简而言之，血液的破坏作用胜过治疗剂的好处。Cerefuse的颠覆性方法旨在降低组织的功能而不依赖于药物对组织产生影响（尽管它们将被用于修改血液的盐分子来修改该项目，但在此项目中，CEREFUSE可以使用动物的功能*设计/组装动物的作用*在最小化RI发生的功效。*开发_in-Vitro_模型以评估血液参数